PAVmed Inc (NASDAQ:PAVM) was the recipient of a large decline in short interest during the month of November. As of November 29th, there was short interest totalling 539,000 shares, a decline of 13.2% from the November 14th total of 621,300 shares. Currently, 2.1% of the company’s stock are sold short. Based on an average trading volume of 176,500 shares, the days-to-cover ratio is presently 3.1 days.
PAVM traded up $0.08 during mid-day trading on Friday, reaching $0.93. 663,130 shares of the stock were exchanged, compared to its average volume of 336,550. The company has a 50 day moving average price of $0.89 and a two-hundred day moving average price of $0.99. PAVmed has a 1 year low of $0.81 and a 1 year high of $1.38.
Institutional investors and hedge funds have recently bought and sold shares of the business. Glassman Wealth Services boosted its holdings in PAVmed by 54.9% during the 3rd quarter. Glassman Wealth Services now owns 32,149 shares of the company’s stock worth $31,000 after acquiring an additional 11,400 shares during the last quarter. CWM LLC boosted its holdings in shares of PAVmed by 206.7% in the 2nd quarter. CWM LLC now owns 46,000 shares of the company’s stock worth $52,000 after buying an additional 31,000 shares during the last quarter. BlackRock Inc. purchased a new position in shares of PAVmed in the 2nd quarter worth about $59,000. Finally, Vanguard Group Inc. boosted its holdings in shares of PAVmed by 174.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,123,483 shares of the company’s stock worth $1,281,000 after buying an additional 714,077 shares during the last quarter. 7.31% of the stock is currently owned by hedge funds and other institutional investors.
Separately, Maxim Group reaffirmed a “buy” rating and set a $3.00 price objective on shares of PAVmed in a report on Friday, November 22nd.
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Featured Story: What is a stock split?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.